A double-blind randomized study evaluated the efficacy of PC-SOD at a dose of 80 mg to prevent peripheral neuropathy in patients with colorectal cancer treated with oxaliplatin [37]. This evidence concerns the gene SOD1 and peripheral neuropathy.